Mylan announces launch of Xulane
PITTSBURGH — Mylan announced the launch of Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), the generic version of Ortho Evra (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day) from Janssen Pharmaceuticals. The drug is used to prevent pregnancy in women who want to use a transdermal patch as a contraception method.
"Mylan is proud to continue expanding its portfolio of transdermal products through the launch of the first generic Ortho Evra Patch. Mylan’s Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), which provides women with a high quality, affordable treatment option, once again demonstrates Mylan’s commitment to bring to market difficult-to-develop and -manufacture medicines in support of our mission to expand access to high quality medicine," Heather Bresch, Mylan CEO, said.
Ortho Evra had sales in the United States of approximately $152.9 million for the 12 months ending Dec. 30, 2013, according to IMS Health.
Teva USA settles with Pfizer on generic Celebrex
JERUSALEM — Teva Pharmaceutical on Thursday announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva’s generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.
Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100-, 200- and 400-mg capsules.
Sales of Celebrex were $2.2 billion in the U.S. according to IMS data as of December, 2013.
CVS/pharmacy’s Rob Price steps down as CMO
WOONSOCKET, R.I. — Rob Price, SVP marketing and advertising and chief marketing officer for CVS/pharmacy, has left the company to take a new role, the retailer said in a statement sent to Drug Store News.
“Rob led the retail marketing team during a period of tremendous growth and strong financial performance and brought numerous positive changes to the business. We thank Rob for his important contributions and wish him the best of luck in the next phase of his career,” the company stated.
With more than 20 years of retail, strategy and marketing experience, Price more tightly integrated the store and digital environments to create a more personalized experience for shoppers and patients at CVS/pharmacy. At the center of this effort are the proprietary insights drawn from CVS/pharmacy’s ExtraCare loyalty program, the largest of its kind. He joined the company in 2006. In October 2011, the company announced that Price had taken on an expanded role in the company with the addition of retail innovation and store design to his responsibilities.
During his time at CVS/pharmacy, his responsibilities included advertising, promotion, marketing, customer relations and consumer research, as well as retail innovation and store design, the CVS.com e-commerce business and the ExtraCare loyalty program.
Among the more recent initiatives launched under Price’s watch is CVS/pharmacy’s new myWeeklyAd, a first-of-its-kind digital circular experience powered by the CVS/pharmacy ExtraCare loyalty program. The myWeekly Ad is a digitized circular program that creates a personalized list of offers based on the actual items an ExtraCare member historically purchases.
In 2012, Price was named to the Aspen Institute’s 2012 Class of Henry Crown fellows. The Henry Crown Fellowship is designed to engage the next generation of leaders in the challenge of community-spirited leadership. It brings together executives from the business world — all entrepreneurs, all younger than 45 years — who have already achieved conspicuous success in their chosen fields and are at a point of inflection in their lives and careers.
Before joining CVS Caremark, Price held marketing and merchandising leadership positions at H-E-B Grocery and Wawa Food Markets.